Last reviewed · How we verify
STRIBILD
Stribild, marketed by Vancouver Infectious Diseases Centre, is a combination antiretroviral therapy for HIV with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and multi-drug formulation, which simplifies treatment regimens for patients. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | STRIBILD |
|---|---|
| Also known as | Co-formulated elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil fumarate, Co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate |
| Sponsor | Vancouver Infectious Diseases Centre |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (PHASE4)
- Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection
- Connecting Resources for Urban Sexual Health (NA)
- Bictegravir in the Elderly Living With HIV (BICEP)
- HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (PHASE4)
- HIV Non-Occupational Post-Exposure Prophylaxis (PHASE4)
- Reducing Antiretroviral Treatments (PHASE3)
- Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STRIBILD CI brief — competitive landscape report
- STRIBILD updates RSS · CI watch RSS
- Vancouver Infectious Diseases Centre portfolio CI